Abstract 3773
Background
It is internationally recognised that centralisation of specialist cancer services results in improved oncologic outcomes, particularly for rare cancers. Ireland’s oncology services were formally centralised into 8 high volume cancer centres in 2007. We sought to identify changes in the utilisation of cancer treatment modalities and outcomes for patients with hepatobiliary cancers in Ireland pre and post centralisation.
Methods
Following local ethics board approval, anonymised patient data was provided by the National Cancer Registry of Ireland (NCRI) regarding all cases of hepatocellular cancer (HCC), cholangiocarcinoma and gallbladder cancers (ICD10: C22, C23 and C24) diagnosed in Ireland between 2000 – 2016. Data analysis was completed in collaboration with the NCRI.
Results
Data from 5733 patients with cholangiocarcinoma, gallbladder cancer and HCC over 16 years were analysed (Table). Similar rates of resection of all cancers were identified (21% pre 2008 and 24% from 2008 -2016). Overall 5-year survival for all cancers evaluated was significantly higher (non-overlapping CI) from 2008 -2016 - 16.1% (95% CI 14.4-17.8%) compared to pre 2008 - 12.6% (95% CI 11.0-14.4%). Despite similar rates of resection, 5-year survival rates for all resected cancers was significantly improved from 2008 - 2016 - 46.0% (95% CI 41.3-50.6%) vs 35.7% (95% CI 30.7-40.6%) prior to this. The most significant changes in use of treatment modality over the time course studied was the number of patients who received chemotherapy only (9% pre 2008 and 19% 2008 -2016, p < 0.01) and the significant increase in the number of patients who underwent adjuvant treatment (21% pre 2008 versus 42% from 2008 - 2016, p < 0.01).Table:
740P
Cancer Subtypes | 2000-2007 | 2008-2016 |
Cholangiocarcinoma | 38% (782) | 41% (1519) |
Hepatocellular Carcinoma | 17% (346) | 21% (780) |
Gallbladder | 19% (379) | 13% (497) |
Unspecified Subtype | 26% (537) | 24% (893) |
Total | 2044 | 3689 |
Conclusions
The establishment of national cancer centres in Ireland in 2007 was associated with improvement in 5-year survival for patients with hepatobiliary malignancies and with increased utilisation of systemic therapy in the advanced and adjuvant settings.
Clinical trial identification
Editorial acknowledgement
We would like to thank all the team at the National Cancer Registry of Ireland for their hard work collecting the data.
Legal entity responsible for the study
St. James’ Hospital, Dublin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3695 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
Presenter: Heinz Josef Lenz
Session: Poster Display session 2
Resources:
Abstract
4250 - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
Presenter: Erika Martinelli
Session: Poster Display session 2
Resources:
Abstract
5234 - The ORCHESTRA trial; A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).
Presenter: Lotte Bakkerus
Session: Poster Display session 2
Resources:
Abstract
5294 - EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers
Presenter: Elizabeth Cartwright
Session: Poster Display session 2
Resources:
Abstract
913 - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses
Presenter: Margaret Tempero
Session: Poster Display session 2
Resources:
Abstract
1668 - FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma : update of the AGEO cohort.
Presenter: Edouard Auclin
Session: Poster Display session 2
Resources:
Abstract
2559 - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT)
Presenter: Hanno Riess
Session: Poster Display session 2
Resources:
Abstract
4897 - Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumor DNA
Presenter: Xiao-ding Liu
Session: Poster Display session 2
Resources:
Abstract
1755 - Evaluation of minimal important difference (MID) for the European Organisation for Research and Treatment of Cancer (EORTC) Pancreatic Cancer Module (PAN26) in patients with surgically resected pancreatic adenocarcinoma
Presenter: Michele Reni
Session: Poster Display session 2
Resources:
Abstract
2876 - Multispectral analysis of lymphocyte complexity in periampullary adenocarcinoma
Presenter: Sebastian Lundgren
Session: Poster Display session 2
Resources:
Abstract